Medicine Prices – Delegates Near Agreement On Softer Resolution For Disclosure 26/05/2019 Elaine Ruth Fletcher After a grueling 34 hours of nearly non-stop negotiations, World Health Assembly delegates appeared to be close to a final agreement Saturday evening on a resolution supporting more systematic disclosure of prices for medicines purchased and sold on national and global markets; a “drafting group” is expected to reconvene Monday morning to put the finishing […] Continue reading -> Little Progress Over Price Transparency Resolution; Negotiators Behind Closed Doors 24/05/2019 Catherine Saez Secrecy was the watchword Friday as countries huddled together behind closed doors trying to reach agreement on a WHA resolution that would shed more sunshine on the real prices of medicines in national and global pharmaceutical markets. Image Credits: Max Pixel, Catherine Saez. Continue reading -> Price Transparency In Medicines Markets – Scrutinizing Evidence Behind The Claims 24/05/2019 Editorial team As the debate over a draft resolution supporting greater price transparency for medicines in national and global markets intensifies, with closed-door consultations among countries at the 72nd World Health Assembly continuing late into the night, Health Policy Watch continues to feature diverse “Inside Views” on this charged issue. Here, Suerie Moon, MPA PhD, faculty member […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> Future Of Drug Pricing Resolution Hangs In Balance At World Health Assembly 23/05/2019 Catherine Saez The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise […] Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Little Progress Over Price Transparency Resolution; Negotiators Behind Closed Doors 24/05/2019 Catherine Saez Secrecy was the watchword Friday as countries huddled together behind closed doors trying to reach agreement on a WHA resolution that would shed more sunshine on the real prices of medicines in national and global pharmaceutical markets. Image Credits: Max Pixel, Catherine Saez. Continue reading -> Price Transparency In Medicines Markets – Scrutinizing Evidence Behind The Claims 24/05/2019 Editorial team As the debate over a draft resolution supporting greater price transparency for medicines in national and global markets intensifies, with closed-door consultations among countries at the 72nd World Health Assembly continuing late into the night, Health Policy Watch continues to feature diverse “Inside Views” on this charged issue. Here, Suerie Moon, MPA PhD, faculty member […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> Future Of Drug Pricing Resolution Hangs In Balance At World Health Assembly 23/05/2019 Catherine Saez The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise […] Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Price Transparency In Medicines Markets – Scrutinizing Evidence Behind The Claims 24/05/2019 Editorial team As the debate over a draft resolution supporting greater price transparency for medicines in national and global markets intensifies, with closed-door consultations among countries at the 72nd World Health Assembly continuing late into the night, Health Policy Watch continues to feature diverse “Inside Views” on this charged issue. Here, Suerie Moon, MPA PhD, faculty member […] Continue reading -> Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> Future Of Drug Pricing Resolution Hangs In Balance At World Health Assembly 23/05/2019 Catherine Saez The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise […] Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Behind The Headlines: How Can Industry Contribute To Cancer Care As Part Of Universal Health Coverage? 24/05/2019 Elaine Ruth Fletcher From preventive screening to the quality of nursing care and the structure of national insurance systems, patients face multiple barriers to cancer prevention, treatment and care, said a high-level panel of experts at a side event on the margins of this week’s World Health Assembly (20-28 May). Image Credits: UnternehmerTUM/@birdyfoto.de. Continue reading -> Future Of Drug Pricing Resolution Hangs In Balance At World Health Assembly 23/05/2019 Catherine Saez The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise […] Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Future Of Drug Pricing Resolution Hangs In Balance At World Health Assembly 23/05/2019 Catherine Saez The fate of a potentially game-changing World Health Assembly resolution that would support greater national and global transparency in drug pricing remained in the balance today as the country co-sponsors tabled a resolution riddled with comments and caveats, and a “drafting group” was urgently formed to huddle on ways to move forward on a compromise […] Continue reading -> How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
How transparency of the costs of clinical trials will improve policy making 23/05/2019 Editorial team [Re-posted from Knowledge Ecology International.] By James Love, Director of Knowledge Ecology International (KEI) – 22 May 2019 Perhaps the toughest issue in the 72nd World Health Assembly negotiations on a WHO transparency resolution concerns the proposal to require public reporting of the costs of each clinical trial undertaken for development of drugs, vaccines, cell- […] Continue reading -> Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Several Ministers Of Health Speak Up For Drug Market Transparency, Lower Prices At WHA Side Event 20/05/2019 Catherine Saez The room holding the high-level side event on transparency of pharmaceutical product markets was overflowing today – with dozens of people standing to hear the speakers – many of them ministers of health, reflecting the importance of the topic at the 72nd World Health Assembly. Image Credits: Catherine Saez. Continue reading -> Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Fair Pricing – Striking The Balance 10/05/2019 Editorial team Thomas Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations, shared his view on fair pricing with Health Policy Watch: “Most of us can probably agree that innovation is meaningless if it does not reach patients. At the same time, a Fair Price must strike a balance between a price that is […] Continue reading -> Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Several Developed Countries Want To “Derail” Transparency Resolution – Civil Society Groups Say 10/05/2019 David Branigan More than 100 civil society organisations and health experts signed on to an open letter yesterday calling out Germany, Sweden, Denmark, the UK and Australia, along with Austria and the United States, as wanting to “derail” and “weaken” the transparency resolution on drug prices and R&D costs. Image Credits: CDDEP. Continue reading -> Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Group Of Developed Countries Seek To Delay Italian Proposal On Drug Price Transparency 07/05/2019 William New A number of developed countries are working to delay a landmark proposal at the World Health Organization by Italy to increase transparency of drug prices and R&D costs in an effort to make medicines more affordable, according to sources. The Italian proposal has garnered a number of supporters, including within Europe; but at an informal WHO consultation today and last week at the European Union, countries such as Germany, France, and the United Kingdom have begun pushing for postponement of discussions, sources said. [Now updated with new version of proposal!] Continue reading -> Posts navigation Older postsNewer posts